Allogene Therapeutics, Inc. (ALLO): who owns it and who trades it
As of Nov 16, 2026, ALLO insiders reported 15 open-market sales worth $669K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was David D Chang (CEO), with $289K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Allogene Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ALLO
207 funds and institutions reported ALLO shares worth $657M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 12.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 30.15M | 12.37% | $62.7M | +58% |
| Frazier Life Sciences Management, L.P. | 22.45M | 9.21% | $46.7M | +491% |
| Pfizer Inc | 22.03M | 9.04% | $46.9M | No change |
| State Street Corp | 19.03M | 7.80% | $39.6M | +120% |
| Tpg Gp A, LLC | 18.72M | 7.68% | $38.9M | No change |
| Sio Capital Management, LLC | 13.32M | 5.47% | $27.7M | – |
| Primecap Management Co | 13.12M | 5.38% | $27.3M | +57% |
| Vanguard Capital Management LLC | 12.17M | 4.99% | $25.3M | +76% |
| FMR LLC (Fidelity) | 12.01M | 4.93% | $25M | +655% |
| Citadel Advisors LLC | 10.09M | 4.14% | $21M | +48% |
| Two Sigma Investments, LP | 7.78M | 3.19% | $16.2M | +45% |
| Geode Capital Management, LLC | 7.05M | 2.89% | $14.7M | +71% |
| Goldman Sachs Group Inc | 6.15M | 2.52% | $12.8M | +122% |
| GordonMD Global Investments LP | 5.30M | 2.17% | $11M | +270% |
| Marshall Wace, LLP | 5.10M | 2.09% | $10.6M | +48% |
| Patient Square Capital LP | 5.05M | 2.07% | $10.5M | +46% |
| Aberdeen Group plc | 5.00M | 2.05% | $10.4M | +242% |
| Millennium Management LLC | 4.84M | 1.99% | $10.1M | +46% |
| D. E. Shaw & Co., Inc. | 4.71M | 1.93% | $9.8M | +70% |
| T. Rowe Price Associates | 4.64M | 1.90% | $9.7M | -14% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ALLO insiders reported $0 of open-market purchases and $669K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | Geoffrey M. Parker | CFO | Sale | 36,342 | $1.34 | $48.7K | Form 4 |
| Aug 21, 2026 | Earl Martin Douglas | Vice president | Sale | 29,697 | $2.12 | $63K | Form 4 |
| Apr 21, 2026 | Annie Yoshiyama | Vice president | Sale | 9,586 | $2.31 | $22.1K | Form 4 |
| Mar 31, 2026 | Benjamin Machinas Beneski | Vice president | Sale | 2,867 | $2.50 | $7.2K | Form 4 |
| Mar 16, 2026 | Benjamin Machinas Beneski | Vice president | Sale | 4,835 | $2.47 | $11.9K | Form 4 |
| Mar 16, 2026 | David D Chang | CEO | Sale | 47,763 | $2.47 | $118K | Form 4 |
| Mar 2, 2026 | Benjamin Machinas Beneski | Vice president | Sale | 7,132 | $2.60 | $18.5K | Form 4 |
| Feb 2, 2026 | Benjamin Machinas Beneski | Vice president | Sale | 7,549 | $1.73 | $13.1K | Form 4 |
| Feb 2, 2026 | David D Chang | CEO | Sale | 95,269 | $1.80 | $171K | Form 4 |
| Feb 2, 2026 | Geoffrey M. Parker | CFO | Sale | 24,001 | $1.76 | $42.2K | Form 4 |
| Feb 2, 2026 | Earl Martin Douglas | Vice president | Sale | 22,900 | $1.76 | $40.3K | Form 4 |
| Feb 2, 2026 | Annie Yoshiyama | Vice president | Sale | 4,167 | $1.72 | $7.2K | Form 4 |
| Feb 2, 2026 | Zachary Roberts | Vice president | Sale | 35,700 | $1.77 | $63.2K | Form 4 |
| Jan 21, 2026 | Zachary Roberts | Vice president | Sale | 26,269 | $1.56 | $41K | Form 4 |
| Nov 17, 2025 | Benjamin Machinas Beneski | Vice president | Sale | 786 | $1.22 | $959 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David D Chang | President and CEO, Director | – | $289K | Mar 16, 2026 |
| Zachary Roberts | EVP of R&D | – | $104K | Feb 2, 2026 |
| Earl Martin Douglas | SVP, General Counsel | – | $103K | Aug 21, 2026 |
| Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | – | $90.9K | Oct 21, 2026 |
| Benjamin Machinas Beneski | SVP, Chief Technical Officer | – | $51.7K | Mar 31, 2026 |
| Annie Yoshiyama | SVP, Finance | – | $29.3K | Apr 21, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALLO short interest
High short interest. 14.8% of ALLO shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 51.29M ALLO shares were sold short, 14.8% of the shares outstanding, down 4.0% from the report before. At the average daily volume of 8.27M shares, buying them all back would take about 6.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 51.29M | 14.84% | -4% | 8.27M | 6.2 |
| Oct 15, 2026 | 53.41M | 15.46% | -4% | 5.78M | 9.2 |
| Sep 30, 2026 | 55.61M | 16.10% | -7% | 6.18M | 9.0 |
| Sep 15, 2026 | 59.60M | 17.25% | +1% | 5.30M | 11.3 |
| Aug 31, 2026 | 59.11M | 17.11% | +0% | 4.87M | 12.2 |
| Aug 14, 2026 | 58.95M | 17.06% | -3% | 4.94M | 11.9 |
| Jul 31, 2026 | 60.75M | 24.92% | +2% | 6.58M | 9.2 |
| Jul 15, 2026 | 59.71M | 24.49% | -6% | 9.40M | 6.3 |
| Jun 30, 2026 | 63.39M | 26.00% | +32% | 12.33M | 5.1 |
| Jun 15, 2026 | 48.04M | 19.70% | +8% | 7.74M | 6.2 |
| May 29, 2026 | 44.48M | 18.25% | +5% | 6.57M | 6.8 |
| May 15, 2026 | 42.28M | 17.34% | +15% | 6.60M | 6.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Allogene Therapeutics company events
Allogene Therapeutics filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 2, 2026LeadershipGeoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc., provided notice of his retirement from the Company in all capacities, effective November 6, 2026. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 22, 2026AnnouncementThe Company filed a prospectus supplement with the Securities and Exchange Commission relating to sales of shares of its common stock having an aggregate offering price of up to $135.0 million to be sold pursuant to a certain Sales Agreement, dated November 5, 2019, as amended on November 2, 2022… Filing
- May 28, 2026LeadershipThe Board of Directors of Allogene Therapeutics, Inc., upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities. Filing
- May 13, 2026AgreementAllogene Therapeutics, Inc. entered into (i) a Termination Agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. and (ii) a Second Amended and Restated Shareholders’ Agreement with Overland Therapeutics Inc. and HH BioPharma Holdings Ltd. Pursuant to the Termination… Filing
- Apr 15, 2026AnnouncementWe entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 87,500,000 shares of our common stock, par value $0.001 per share. Filing
- Apr 13, 2026AnnouncementAllogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. Filing
- Apr 13, 2026AnnouncementAllogene Therapeutics, Inc. announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel in first-line consolidation for large B-cell lymphoma. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Allogene Therapeutics financials
Famous investors that hold ALLO
4 of the 50 well-known investors we track reported holding ALLO in their latest 13F filing. The largest position is Ken Griffin's, worth $39.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 24.56M | $39.3M | 0.0% | +143% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 5.23M | $8.4M | 0.0% | +36% |
| Israel Englander · Millennium Management | Q3 2026 | 5.12M | $8.2M | 0.0% | +6% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 368,461 | $590K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ALLO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Citadel Securities GP LLC | 13G | 4.7% |
| Nov 16, 2026 | Citadel Securities GP LLC | 13G | 4.7% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.7% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.7% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.7% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 6.7% |
Questions about Allogene Therapeutics, Inc. (ALLO) stock
Who owns the most ALLO stock?
The largest reported owner of Allogene Therapeutics, Inc. (ALLO) is BlackRock, Inc., with 12.4% of the company. In total, 207 funds and institutions reported holding ALLO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ALLO insiders buying or selling?
In the last 12 months, ALLO insiders reported no open-market purchases and 15 sales worth $669K. The latest trade was on Oct 21, 2026. See every trade.
What is the short interest in ALLO?
As of Oct 30, 2026, 51.29M ALLO shares were sold short, 14.8% of the shares outstanding, down 4.0% from the report before. At the average daily volume of 8.27M shares, buying them all back would take about 6.2 trading days (days to cover). See the history.
Which famous investors hold ALLO?
4 of the 50 well-known investors we track reported ALLO in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $39.3M. See all holders.
Executive pay
Allogene Therapeutics's chief executive was paid a total of $6.1M for the year ended Dec 31, 2025, up 37% from $4.5M the year before. In the last 12 months, Allogene Therapeutics's executives and directors bought no stock on the open market and sold $669K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.